奥马珠单抗治疗过敏性疾病
作者: |
1杨琰茗,
1任丹阳,
2翁稚颖,
1涂彩霞,
1沈建玲,
1李云巍,
1刘艳,
1李惠英
1 昆明医科大学附属儿童医院药剂科,昆明 650000 2 昆明医科大学药学院暨云南省天然药物药理重点实验室,昆明 650000 |
通讯: |
李惠英
Email: lihuiying@etyy.cn |
DOI: | 10.3978/j.issn.2095-6959.2022.07.035 |
摘要
Omalizumab for allergic diseases
CorrespondingAuthor: LI Huiying Email: lihuiying@etyy.cn
DOI: 10.3978/j.issn.2095-6959.2022.07.035
Abstract
The incidence of allergic diseases is increasing globally and has been listed by the World Health Organization as one of the three major diseases for prevention and treatment in the 21st century. IgE is an important mediator of allergic reactions and an important target for clinical treatment of allergic diseases. Omalizumab slows or prevents IgE-mediated allergic reactions by targeting free IgE binding and down-regulating IgE high-affinity receptors on effector cells. The resistance mechanism of omalizumab in the treatment of allergic disease work provides a strong theoretical foundation, in allergic asthma, allergic rhinitis and chronic idiopathic urticaria and atopic dermatitis, food allergies and other IgE mediated show a great clinical potential in allergic disease, has a good application prospect and popularization significance.